Please login to the form below

Not currently logged in
Email:
Password:

Merck collaborate over betrixaban

Merck and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for betrixaban

Global research-driven pharmaceutical company, Merck & Co, and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for the development and commercialisation of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in phase II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).

In return for an exclusive worldwide license to betrixaban, Merck will pay Portola an initial fee of $50m. Portola is also eligible to receive additional cash payments amounting to $420m on achievement of certain development, regulatory and commercialisation milestones, as well as double-digit royalties on worldwide sales of betrixaban, if approved. Merck will assume all development and commercialisation costs, including the costs of phase III clinical trials, however, Portola has retained an option to co-fund phase III clinical trials in return for additional royalties and to co-promote betrixaban with Merck in the US.

According to Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular at Merck Research Laboratories: "This agreement reinforces Merck's focus on developing an innovative portfolio of products for the treatment and management of multiple aspects of cardiovascular disease."

13th July 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....